NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Investors of record on Friday, June 15th will be given a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.12%. The ex-dividend date is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. declared that its Board of Directors has approved a share buyback plan on Saturday, December 2nd 2017, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase plans are often an indication that the company's leadership believes its shares are undervalued.

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.00 by $0.05. The firm earned $10.04 billion during the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co., Inc. had a net margin of 4.31% and a return on equity of 30.93%. The company's revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.88 earnings per share. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 Wall Street analysts have issued 1-year price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $56.00 to $72.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $65.8644 in the next year. View Analyst Ratings for Merck & Co., Inc..

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), GlaxoSmithKline (GSK), Sanofi (SNY), Bayer (BAYRY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Media coverage about MRK stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co., Inc. earned a coverage optimism score of 0.11 on Accern's scale. They also assigned press coverage about the company an impact score of 48.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Merck & Co., Inc.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.85%), Franklin Resources Inc. (1.82%), Northern Trust Corp (1.24%), Boston Partners (0.55%), Legal & General Group Plc (0.50%) and Barrow Hanley Mewhinney & Strauss LLC (0.47%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Federated Investors Inc. PA, Northern Trust Corp, Boston Partners, Barrow Hanley Mewhinney & Strauss LLC, Swiss National Bank, Independent Franchise Partners LLP and Legal & General Group Plc. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Pzena Investment Management LLC, Natixis, Manning & Napier Group LLC, Levin Capital Strategies L.P., American Century Companies Inc., Sound Shore Management Inc. CT and Summit Trail Advisors LLC. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $61.47.

Merck & Co., Inc. has a market capitalization of $165.22 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]